NICE u-turn backs use of Teva’s asthma biologic

July 21, 2017  Source: pharmatimes 405

The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.

The cost regulator has issued a Final Appraisal Determination outlining its support for Cinqaero (reslizumab) to treat patients with severe eosinophilic asthma, where inflammation and narrowing of the airways can result in uncontrolled symptoms and serious asthma attacks.

In November NICE said it was minded not to recommend its routine use by the NHS, and asked for further clarification and an updated cost-effectiveness model for its appraisal of the therapy.

Cinqaero is a humanised interleukin-5 (IL-5) antagonist monoclonal antibody approved in Europe in August 2016 as add-on therapy for patients inadequately controlled despite high-dose inhaled corticosteroids plus another maintenance therapy, on the back of data showing statistically significant reductions in the frequency of clinical asthma exacerbations compared to placebo.

Uncontrolled asthma impacts a large number of patients, presenting a major challenge for clinicians and a significant burden on healthcare systems. According to Teva, it is estimated that the market for severe asthma biotech drugs could exceed $7.5 billion a year in the US and Europe alone.

 

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.